Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Scrip Asks…What Does 2024 Hold For Biopharma? Part 5: Clinical Trial Trends

Digital And Data Revolution Drives Change

Executive Summary

Some 50 experts and executives in the biopharma sector shared their views on the major trends they expect to see driving change in the clinical trials arena in 2024. Artificial intelligence applied to clinical development, greater use of remote monitoring and increased patient diversity in trials were key themes.

You may also be interested in...



Avance Clinical CEO On Biotech Funding Green Shoots, Oncology Study Design Landscape

Avance Clinical’s CEO talks to Scrip about green shoots in US biotech funding, potential partnering in the AI space, the Australia rapid-start draw for early phase trials and the transition in the study design landscape in oncology for first-in-human trials.

A Question Of Intent: How To Avoid US FDA Pitfalls With Academic Oncology Trials

Academic oncology centers and commercial sponsors should work together to ensure that studies begun without ‘registrational intent’ can nevertheless work for US FDA’s needs if circumstances change, a multi-stakeholder white paper urges.

UK Trial Inclusion And Diversity Plans To Have ‘Wider Scope’ Than Those In US

The UK is developing a set of questions and supporting guidance on inclusion and diversity for sponsors to consider when they design clinical trials and clinical investigations. Sponsors will be required to consider aspects beyond participants’ race and ethnicity.

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

SC149726

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel